ArticleCirculation. Population health and outcomes2026
Statins Use in Veterans With Peripheral Artery Disease: Insights From the PEARLS Study.
Article in Circulation. Population health and outcomes, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
backgroundGuidelines recommend high-intensity statins in patients with peripheral artery disease (PAD). We examined contemporary use of statins among real-world patients with a new diagnosis of PAD.
methodsWithin a national registry of Veterans with incident PAD, we used pharmacy claims data to determine active statin use within 1 year of PAD diagnosis. We also used laboratory data to evaluate lipid levels. Hierarchical multivariable logistic regression was used to identify variables associated with the use of any statin and high-intensity statin 1 year after PAD diagnosis and quantify variation in statin use across sites.
resultsAmong 91 970 patients with PAD alive at 1 year, the median age was 70 years, 97.2% were men, and 18.6% were Black. At 1 year, 64 231 (69.9%) patients were on a statin, and 34 017 (37.0%) were on a high-intensity statin. Among nonstatin users, 53.4% (14 834/27 739) had not been prescribed a statin at any time in the preceding 3 years. Overall, the median low-density lipoprotein cholesterol was 81.6 mg/dL and was lower in those on high-intensity statins versus low/moderate-intensity statins versus no statins (72.2 versus 78.0 versus 100 mg/dL). Age, prior history of coronary artery disease, cerebrovascular disease, hypertension, diabetes, and current or former smoking history, obesity, and revascularization during the initial 6 months were associated with higher statin and high-intensity statin use (among statin users). At the site level, there was modest variation in statin use, especially high-intensity statins, which ranged from 20% to 54% with an overall median odds ratio of 1.39 (95% CI, 1.32-1.46).
conclusionsNearly 70% of patients with PAD were receiving a statin within 1 year of PAD diagnosis. However, use of high-intensity statins and nonstatin lipid-lowering therapy remained suboptimal. Moreover, there was modest variation in use of statins, especially high-intensity statins, across sites, highlighting opportunities for improving guideline-concordant care in patients with PAD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.